Esperion Therapeutics, Inc. (ESPR)
| Previous Close | 1.4400 |
| Open | 1.4400 |
| Bid | 1.5200 x 3200 |
| Ask | 1.5300 x 4000 |
| Day's Range | 1.4400 - 1.6100 |
| 52 Week Range | 0.7000 - 8.8700 |
| Volume | |
| Avg. Volume | 3,858,760 |
| Market Cap | 172.915M |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2700 |
| Earnings Date | Feb 19, 2024 - Feb 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 |
Simply Wall St.Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Profit Outlook
With the business potentially at an important milestone, we thought we'd take a closer look at Esperion Therapeutics...
GlobeNewswireEsperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation – – 21.6% Reduction in Vascular Inflammatory Marker High Sensitivity C-reactive Protein (hsCRP) in Patients Taking Bempedoic Acid – – Results Simultaneously Published in Circulation – ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Esper
- GlobeNewswire
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced participation in the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized control trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndr
